Table 3.
Patient | Age (years) | Origin | Fever | Therapy | Vitamin D supplementation | Comorbidities | Fractures | Severe osteoporosis | Hospitalization | Death | Serum 25-OH- Vitamin D (ng/ml) |
---|---|---|---|---|---|---|---|---|---|---|---|
#1 | 87 | AV2 | Yes | Denosumab | Yes | HT | No | Yes | No | No | 25 |
#2 | 79 | AV2 | Yes | Denosumab | Yes | - | V, F | Yes | No | No | 22 |
#3 | 64 | AV2 | Yes | IVBP | Yes | HT | No | No | No | No | 29 |
#4 | 81 | AV2 | No | Denosumab | Yes | - | No | No | Yes | No | 19 |
#5 | 80 | AV2 | Yes | Denosumab | No | DMHTHeart diseaseHTC | No | No | Yes | No | 18 |
#6 | 70 | AV2 | Yes | Denosumab | Yes | HT | No | No | Yes | No | 20 |
#7 | 76 | AV2 | Yes | Denosumab | Yes | HTC | V, O | No | Yes | No | 26 |
#8 | 87 | AV3 | Yes | IVBP | Yes | HTHTC | V, O | Yes | Yes | No | 18 |
#9 | 89 | AV2 | Yes | Denosumab | Yes | HTHeart disease | V, O | Yes | Yes | Yes | 12 |
#10 | 86 | AV2 | Yes | Denosumab | Yes | - | V, O | Yes | Yes | Yes | 18 |
IVBP: intravenous bisphosphonates; V: vertebral; F: femoral; O: Other sites; HT: hypertension; DM: diabetes mellitus; HTC: hormone therapy for cancer